Alphamab Oncology (HKSE:09966) Research & Development: HK$629.1 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09966 Alphamab Oncology HKSE:09966
55 GF Score
Price HK$8.35
GF Value HK$7.81
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Alphamab Oncology Research & Development?

Alphamab Oncology HKSE:09966 +2.58% 55 Research & Development is HK$629.1 Mil as of Dec. 2025. GuruFocus rates HKSE:09966 with a GF Score™ of 55/100 and a GF Value™ of HK$7.81 (Fairly Valued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Alphamab Oncology's Research & Development for the six months ended in Dec. 2025 was HK$352.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$629.1 Mil.

Alphamab Oncology  (HKSE:09966) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Alphamab Oncology Research & Development Related Terms

Alphamab Oncology Research & Development Historical Data

* Premium members only.

The historical data trend for Alphamab Oncology's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alphamab Oncology Research & Development Chart

Alphamab Oncology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 589.41 522.89 445.74 431.50 632.08

Alphamab Oncology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 232.80 209.42 223.81 276.72 352.41
HKSE:09966
55GF Score
Alphamab Oncology HKSE:09966
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alphamab Oncology Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$629.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$629.1 Mil mean?
Alphamab Oncology (HKSE:09966) has a Research & Development of HK$629.1 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Alphamab Oncology and its competitors.
Is Alphamab Oncology's Research & Development too high?
Alphamab Oncology's current Research & Development is HK$629.1 Mil. Overall, Alphamab Oncology has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's Research & Development compare to VRTX and REGN?
Alphamab Oncology's Research & Development of HK$629.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Alphamab Oncology and its competitors. Alphamab Oncology's current Research & Development is HK$629.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Based on GuruFocus' analysis, Alphamab Oncology (HKSE:09966) is currently considered Fairly Valued. The stock's GF Value™ is HK$7.81, compared to a current price of HK$8.35 — trading 6.9% above its estimated fair value. The current Research & Development is HK$629.1 Mil. Alphamab Oncology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Alphamab Oncology (HKSE:09966), the current Research & Development is HK$629.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alphamab Oncology (HKSE:09966) Overvalued in 2026?

Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued. The current stock price of HK$8.35 is trading 6.9% above its estimated GF Value™ of HK$7.81. GuruFocus considers Alphamab Oncology to be Fairly Valued.

Key valuation signals for HKSE:09966:

  • Research & Development: HK$629.1 Mil
  • GF Value™: HK$7.81 vs. price of HK$8.35 (6.9% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the HKSE:09966 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alphamab Oncology Business Description

Other Exchanges 3NK:Germany
Address No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
55GF Score

Get the complete analysis for HKSE:09966

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$8.35
Price
HK$7.81
GF Value